Please upgrade your browser.
Exelixis, Inc. today announced that it has agreed to a request from GlaxoSmithKline (GSK) to initiate its review of XL880 before the compound reaches proof-of-concept. Exelixis expects to deliver the appropriate diligence information to GSK in mid-September, at which point GSK will begin its review to determine whether or not to select XL880 for further development and commercialization. Source: Exelixis, Inc. and earthtimes.org
Surgeons specializing in laparoscopic procedures at UT Southwestern Medical Center have successfully removed a patients kidney by performing a unique nephrectomy entirely through the belly button. Dr. Jeffrey Cadeddu, associate professor of urology and radiology, performed the single keyhole access surgery, the first of its kind involving a kidney. The entire procedure was completed with only one incision and will leave the patient with a barely noticeable scar tucked in the umbilicus, or navel. Source: UT Southwestern Medical Center
Patients with advanced kidney cancer and gastrointestinal stromal tumours in British Columbia will be the first in Canada to benefit from coverage for the medication Sutent (sunitinib) or Nexavar (sor
FreeConferenceCall.com Serves as Critical Communications Conduit in the Battle Against Kidney Cancer
Kidney Cancer Association Optimizes FREE Conferencing Tool for Dissemination of Information to Patients, Doctors and Board Members
Scientists and regulators collaborate to bring a new generation of powerful early diagnosis tools to the clinic. Source: Drug Discovery & Development magazine: Vol. 10, No. 8, August, 2007, pp. 16-20.
Penn State Football Uplifting Athletes Hosts Successful Fundraising Event; Nearly 3,000 Fans Unite to Help Raise Awareness For Kidney Cancer!
|Powered by NeonCRM|